On the stock market since 1996, it operates in the world of health and science. It has 188 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 66% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $169.1M a year. A small number, but proof the product has real buyers.
There is $73.8M in the vault; even if every debt were paid off, $72.1M would remain.
A loss of $48.8M against $169.1M in annual sales.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
Over the last 12 months, executives reported 78 sells against just 23 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, AVDL sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AVDL is a high-risk stock — not yet profitable, and its future rides on its product catching on.